The interferon-α signature of systemic lupus erythematosus

Lupus - Tập 19 Số 9 - Trang 1012-1019 - 2010
Gerlinde Obermoser1, Virginia Pascual2
1Baylor Institute for Immunology Research, Dallas, TX, USA, , Department of Dermatology, University Hospital Innsbruck, Innsbruck Medical University, Austria
2Baylor Institute for Immunology research, Dallas, TX, USA

Tóm tắt

Systemic lupus erythematosus (SLE) is a prototypic multisystem autoimmune disorder where interplay of environmental and genetic risk factors leads to progressive loss of tolerance to nuclear antigens over time, finally culminating in clinical disease. The heterogeneity of clinical manifestations and the disease’s unpredictable course characterized by flares and remissions are very likely a reflection of heterogeneity at the origin of disease, with a final common pathway leading to loss of tolerance to nuclear antigens. Impaired clearance of immune complexes and apoptotic material and production of autoantibodies have long been recognized as major pathogenic events in this disease. Over the past decade the type I interferon cytokine family has been postulated to play a central role in SLE pathogenesis, by promoting feedback loops progressively disrupting peripheral immune tolerance and driving disease activity. The identification of key molecules involved in the pathogenesis of SLE will not only improve our understanding of this complex disease, but also help to identify novel targets for biological intervention. Lupus (2010) 19, 1012—1019.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMra071297

10.1038/gene.2009.39

10.1038/nrg2571

10.1038/ng.468

10.1038/ni.1833

10.1038/ng1020

10.1073/pnas.0701266104

10.1056/NEJMoa073003

10.1038/ng.81

10.1056/NEJMoa0707865

10.1038/ng.79

10.1038/ng.71

10.1016/j.cell.2008.06.032

10.1111/j.1365-2796.2009.02096.x

10.1073/pnas.0901181106

10.1038/sj.gene.6364453

10.4049/jimmunol.179.7.4704

10.4049/jimmunol.0713370

10.1016/S1074-7613(00)80278-2

10.1056/NEJMoa021933

10.1084/jem.179.4.1317

10.1084/jem.190.6.815

10.1126/science.1092385

10.1038/nrmicro1710

10.1084/jem.108.6.925

10.1172/JCI6801

10.4049/jimmunol.175.9.5857

10.1056/NEJM200104123441506

10.1146/annurev.immunol.22.012703.104549

10.1007/s00281-006-0040-5

10.1002/art.24852

10.1016/j.immuni.2006.08.008

10.1146/annurev.immunol.23.021704.115843

10.1038/sj.icb.7100099

10.1016/j.immuni.2006.08.014

10.1126/science.6176024

10.1111/j.1365-2796.1990.tb00144.x

10.1046/j.1365-2249.1999.00772.x

Vallin H., 1999, J Immunol, 163, 6306, 10.4049/jimmunol.163.11.6306

10.1084/jem.194.12.f59

10.1002/art.20254

10.1126/science.284.5421.1835

10.1073/pnas.0337679100

10.1084/jem.20021553

10.1038/ng2091

Feng D., 2010, Arthritis Rheum, 62, 562, 10.1002/art.27223

10.1046/j.1440-1711.2002.01112.x

10.1016/j.immuni.2006.08.010

10.1002/art.24557

10.1097/BOR.0b013e32832e089e

10.1038/11360

10.1146/annurev.immunol.23.021704.115633

10.1084/jem.194.6.863

10.1189/jlb.0603255

10.1038/nature03547

10.1038/nature03464

10.1177/0961203308090020

10.1084/jem.185.6.1101

10.1084/jem.194.12.1823

10.1006/jaut.1998.0215

10.1126/science.1064890

10.1191/096120301678416042

10.1016/S0002-9440(10)61689-6

10.1002/art.23186

10.1111/j.1365-2133.2008.08873.x

10.1038/76032

10.1038/ng0598-56

Lande R., 2007, Nature, 449

10.1038/ni1457

10.1038/ni1028

10.4049/jimmunol.171.6.3296

10.1172/JCI23025

Sano H., 1982, J Immunol, 128, 1341, 10.4049/jimmunol.128.3.1341

10.1084/jem.20050914

10.1084/jem.20051696

10.1038/nri1957

10.1182/blood-2005-07-2650

10.1111/j.1600-065X.2007.00572.x

10.1038/nri2358

10.1111/j.1600-065X.2008.00630.x

10.1016/j.addr.2008.12.008

10.1002/eji.200425218

10.1002/art.22157

10.1146/annurev.immunol.18.1.767

10.1084/jem.191.10.1777

10.1084/jem.20040165

10.1016/j.immuni.2009.11.009

10.1002/art.20745

10.1084/jem.20090480

10.1016/S1074-7613(03)00208-5

10.1038/416603a

10.1038/nm1590